SecBot SecBot
8-K ·Filed Jul 13, 2026

EWTX

Edgewise Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001104659-26-082902
8-K material event: Items 2.01
Actionable Insight ▲ Bullish

The cash infusion eliminates near-term financing risk and provides a clear catalyst path for EDG-7500. Traders should watch for Phase 3 initiation in Q4 2026 and potential milestone payments from Servier. The GRAND CANYON pivotal cohort top-line data for sevasemten (now owned by Servier) is also expected in Q4 2026, which could trigger milestone payments to Edgewise.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

EWTX drug pipeline →

EDG-15400

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unlikely before 2029-2030 at earliest — Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
Next catalyst
None dated

What to watchEDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$41.27
T+0 close · Jul 13, 2026 · via day close
Latest settled
−3.03%
T+60 · $40.02
Vs SPY
−7.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $41.27entry
  2. T+1 · 4mo ago −3.73%α −4.09% · $39.73
  3. T+5 · 4mo ago −3.66%α −2.87% · $39.76
  4. T+20 · 3mo ago +8.02%α +4.84% · $44.58
  5. T+60 · 6w ago −3.03%α −7.02% · $40.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for total potential consideration of up to $2.65 billion. The transaction transforms Edgewise into a cardiovascular-focused company and is expected to fully fund EDG-7500 development through potential approval. The closing removes deal risk and provides a strong cash runway.

Key Facts

  • Edgewise received $1.55 billion in upfront cash from Servier for the sevasemten program.
  • Up to $1.1 billion in additional regulatory and commercial milestones, for aggregate potential consideration of up to $2.65 billion.
  • Transaction closed on July 10, 2026, as previously announced on June 1, 2026.
  • Company is now a cardiovascular-focused biopharma with pipeline including EDG-7500, EDG-15400, and EDG-003.
  • Phase 3 trial of EDG-7500 expected to initiate in Q4 2026; Phase 2 trial of EDG-15400 in HFpEF on track.
  • Upfront proceeds plus existing cash expected to fully fund EDG-7500 development through potential approval.

Financial Impact

Edgewise receives $1.55 billion upfront cash, strengthening balance sheet by approximately 32% of pre-deal market cap ($4.9B). Total potential consideration up to $2.65 billion.

cashrevenuedilution

Risk Factors

  • Milestone payments are contingent on regulatory and commercial success of sevasemten under Servier.
  • Edgewise is now dependent on earlier-stage cardiovascular pipeline (EDG-7500, EDG-15400) with no approved products.
  • Clinical trial risks for EDG-7500 and EDG-15400 could delay or derail the pipeline.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-082902
Document: tm2620181d1_ex99-1.htm0001104659-26-082902
Document: 0001104659-26-082902-index-headers.html0001104659-26-082902
Document: 0001104659-26-082902-index.html0001104659-26-082902
Document: 0001104659-26-082902.txt0001104659-26-082902

Track record

14 reports on EWTX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 144 Neutral 1/10 Entry $43.68 Now $43.68 +0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  4. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
  6. Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  7. Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
  9. Jul 13, 202618w ago 8-K Bullish 7/10 Viewing Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
  10. Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026